glp 1 neurodegenerative disease GLP-1 Agonists Show Promise in Treatment of Disorders Glucagon-like peptide-1 medicines in neurological
Description
Ultimately, the decision to pursue specific interventions should be made in consultation with your healthcare provider, carefully weighing individual health factors, potential risks and benefits, and treatment goals
Indeed, the chronotropic effects of GLP-1RAs may be deleterious in HF patients, with higher sympathetic activity contributing to morbidity and mortality [20]
Huang, Y., Hu, D., Huang, C
They may also slightly increase heart rate
doi: 10.1038/s41575-022-00658-y 6 AdolphTEMeyerMJukicATilgH
[DOI] [PubMed] [Google Scholar] 48.Gonzlez N., Acitores A., Sancho V., Valverde I., Villanueva-Peacarrillo M.L
